Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

被引：2

作者：

Jurczak, Wojciech ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Gaidano, Gianluca ^{[3
]}

Goy, Andre ^{[4
]}

Provencio, Mariano ^{[5
]}

Nagy, Zsolt ^{[6
]}

Robak, Tadeusz ^{[7
]}

Maddocks, Kami J. ^{[8
]}

Buske, Christian ^{[9
]}

Ambarkhane, Sumeet ^{[10
]}

Winderlich, Mark ^{[10
]}

Dirnberger-Hertweck, Maren ^{[10
]}

Endell, Jan ^{[10
]}

Blum, Kristie A. ^{[8
]}

机构：

[1] Jagiellonian Univ, Dept Hematol, Krakow, Poland

[2] Univ Bologna, Inst Hematol, Bologna, Italy

[3] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy

[4] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[5] Univ Hosp Puerta Hierro, Dept Med Oncol, Madrid, Spain

[6] Semmelweis Univ, First Dept Internal Med, Budapest, Hungary

[7] Med Univ Lodz, Dept Hematol, Lodz, Poland

[8] Ohio State Univ Comprehens Canc Ctr, Div Hematol, Dept Internal Med, Columbus, OH USA

[9] Univ Hosp Ulm, Inst Expt Canc Res, Comprehens Canc Ctr Ulm, Ulm, Germany

[10] MorphoSys AG, Martinsried, Germany

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.623.623

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

623

引用

页数：6

共 50 条

[31] Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6
Andorsky, David Jacob
Boccia, Ralph V.
Lash, Bradley Walter
Vaidya, Rakhee
Gandhi, Mitul
Patel, Ameet
Ibrahimi, Sami
Madueno, Fernando Manuel Vargas
Lee, Christina Y.
Naik, Seema
Haydu, J. Erika
Fesler, Mark
Osei-Bonsu, Kojo
Conte, Kristin
Doerr, Thomas
Bai, Yang
Sacchi, Mariana
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[32] B-MIND: MOR208 plus bendamustine (BEN) versus rituximab (RTX) plus BEN in patients with relapsed or refractory (R-R) diffuse large B-cell lymphoma (DLBCL): An open-label, randomized phase trial.
Nowakowski, Grzegorz S.
Belada, David
Molina, Lysianne
Kopeckova, Katerina
Laribi, Kamel
del Campo Garcia, Raquel
Coiffier, Bertrand
Jurczak, Wojciech
Rummel, Mathias J.
Hess, Georg
Rosenwald, Andreas
Winderlich, Mark
Korolkiewicz, Roman
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[33] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
BLOOD, 2022, 140 : 7906 - 7907
[34] Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin's lymphoma (RR-NHL).
Lin, Vincent
Oak, Bhagyashree
Snider, Julia
Epstein, Josh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[35] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[36] Update of the single-arm phase II L-MIND study of MOR208+lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patient subgroups with poor prognosis.
Maddocks, Kami J.
Duell, Johannes
Barca, Eva Gonzalez
Jurczak, Wojciech
Liberati, Anna Marina
Nagy, Zsolt
Obr, Ales
Gaidano, Gianluca
Andre, Marc
Kalakonda, Nagesh
Dreyling, Martin H.
Zinzani, Pier Luigi
Dirnberger-Hertweck, Maren
Weirather, Johannes
Ambarkhane, Sumeet Vijay
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[37] A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results
Hernandez-Ilizaliturri, Francisco J.
Flinn, Ian W.
Kuruvilla, John
Assouline, Sarit E.
Ulrickson, Matthew L.
Christian, Beth A.
Landsburg, Daniel J.
Stuart, Monic
Lowman, Henry
Levin, Nancy
BLOOD, 2020, 136
[38] Bendamustine Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (B-NHL) and Mantle Cell Lymphoma (MCL): Final Results of a Japanese Multicenter Phase II Study.
Ogura, Michinori
Uchida, Toshiki
Ando, Kiyoshi
Ohmachi, Ken
Itoh, Kuniaki
Kubota, Nobuko
Ishizawa, Kenichi
Yamamoto, Joji
Watanabe, Takashi
Uike, Naokuni
Choi, Ilseung
Terui, Yasuhito
Usuki, Kensuke
Nagai, Hirokazu
Uoshima, Nobuhiko
Tobinai, Kensei
BLOOD, 2009, 114 (22) : 1422 - 1422
[39] Multicenter phase II study of oral fludarabine phosphate (FAMP) in relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL)
Morishima, Y
Ogura, M
Tobinai, K
Minami, H
Hayashi, M
Hotta, T
ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
[40] An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
Witzig, T. E.
Vose, J. M.
Zinzani, P. L.
Reeder, C. B.
Buckstein, R.
Polikoff, J. A.
Bouabdallah, R.
Haioun, C.
Tilly, H.
Guo, P.
Pietronigro, D.
Ervin-Haynes, A. L.
Czuczman, M. S.
ANNALS OF ONCOLOGY, 2011, 22 (07) : 1622 - 1627

← 1 2 3 4 5 →